STOCK TITAN
  1. Home
  2. News
  3. SDGR

Schrodinger Inc - SDGR STOCK NEWS

Welcome to our dedicated news page for Schrodinger (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Schrodinger's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Schrodinger's position in the market.

News
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) granted non-statutory stock options to purchase 1,800 shares of the company’s common stock and restricted stock units (RSUs) with respect to 2,250 shares of the company’s common stock to three newly hired employees. The stock options have an exercise price of $31.37 per share, a ten-year term, and vest over four years. The RSUs also vest over four years, with 25 percent vesting after 12 months of continuous service and the balance vesting in successive installments. These grants were made as a material inducement to the employees’ acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
none
-
News
Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event
Rhea-AI Summary
Schrödinger (Nasdaq: SDGR) presents data on SGR-1505's Phase 1 study, expansion of portfolio with EGFRC797S, PRMT5-MTA, and NLRP3 programs, and development efforts targeting synthetic lethality and DNA-damage repair mechanisms. The company also outlines anticipated milestones and provides a detailed review of its proprietary drug discovery and development programs during its Pipeline Day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.09%
Tags
none
-
News
Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting
Rhea-AI Summary
Schrödinger (Nasdaq: SDGR) announced new preclinical data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor, at the American Society of Hematology 65th Annual Meeting. Both candidates show favorable attributes and potential for combination activity with standard-of-care agents. The company also reported preliminary pharmacodynamic data from the Phase 1 study of SGR-1505 in healthy subjects. SGR-1505 and SGR-2921 are now being evaluated in Phase 1 clinical studies for B-cell malignancy and acute myeloid leukemia or myelodysplastic syndrome, respectively. The presentation at ASH demonstrated the potency of SGR-1505 and SGR-2921, with SGR-1505 showing greater modulation of NF-ΚΒ and related pathway genes compared to JNJ-6633, and SGR-2921 exhibiting significant anti-leukemic responses in patient-derived AML models. Schrödinger will provide additional data from the healthy subject study at its Pipeline Day on December 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) Grants Stock Options and Restricted Stock Units to Newly Hired Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
-
News
Schrödinger to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Schrödinger (Nasdaq: SDGR) announced its participation in two upcoming conferences in November. The company will have a fireside chat at the Jefferies London Healthcare Conference on November 15, 2023, at 9:30 a.m. GMT, and a fireside discussion at the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023, at 9:30 a.m. ET. The discussions can be accessed on Schrödinger's website and will be archived for approximately seven days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
conferences
-
News
Schrödinger to Present New Data for SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting
Rhea-AI Summary
Schrödinger (Nasdaq: SDGR) announced that new data on its investigational MALT1 inhibitor, SGR-1505, and CDC7 inhibitor, SGR-2921, will be presented at the ASH 65th Annual Meeting. The data support the continued development of SGR-1505 as a potential therapy for advanced B-cell malignancies. Additionally, SGR-2921 demonstrates strong anti-leukemic activity in preclinical models of AML. Schrödinger will review these data as part of its Pipeline Day on December 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.69%
Tags
conferences
News
Schrödinger Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) reported total revenue of $42.6 million for the third quarter of 2023. The company maintains its full-year 2023 revenue guidance. Progress was made for SGR-1505, with healthy volunteer data expected in the fourth quarter of 2023. Phase 1 study was initiated for SGR-2921. Schrödinger also disclosed the PRMT5-MTA Discovery Program. BMS returned two programs from collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.69%
Tags
earnings
-
News
Schrödinger to Host Pipeline Day on December 14, 2023
Rhea-AI Summary
Schrödinger (Nasdaq: SDGR) will host its Pipeline Day in New York City on December 14, 2023. The event will feature a detailed review of the company's development programs, including updates on SGR-1505, SGR-2921, SGR-3515, and multiple proprietary discovery programs. It will be a hybrid event with limited in-person attendance and a simultaneous webcast for virtual participation. The live presentation can be accessed on Schrödinger's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences
-
News
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Schrödinger, Inc. has granted non-statutory stock options and restricted stock units (RSUs) to newly hired employees as part of their employment compensation. The stock options have an exercise price of $24.61 per share and a ten-year term, vesting over four years. The RSUs also vest over four years, with 25 percent vesting after 12 months of continuous service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
News
Schrödinger to Announce Third Quarter 2023 Financial Results on November 1
Rhea-AI Summary
Schrödinger to report Q3 2023 financial results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.84%
Tags
earnings
Stock SDGR logo
Schrodinger Inc

Nasdaq:SDGR

SDGR Rankings

#1990 Ranked by Market Cap
#2664 Ranked by Stock Gains
N/A Ranked by Dividends

SDGR Stock Data

1.91B
61.36M
2.42%
92.55%
8.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About SDGR

schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. the predictive power of schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries that might otherwise not be possible. schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech company nimbus therapeutics. through significant long-term investments in basic research, schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. hundreds of peer-reviewed scientific publications by schrödinger scientists are frequently among the most heavily cited in their fields. founded in 1990, schrödinger has operations in the us, europe, japan, and india, with business part